SR9009, also known as Stenabolic, is a SARM that was developed at the Scripps Research Institute. It is a PPAR alpha modifier very similar GW-501516. It binds to the Rev-erbα protein, which influences lipid and glucose metabolism in the liver and the creation of fat-storing cells.
Stenabolic has been found to increase mitochondria, the powerhouses of your cells. Once mice were given Stenabolic, they were able to run for 50% longer than non-treated mice. It has also been found to aid weight loss.
GW-501516, also known as Cardarine, is a PPAR agonist that has been shown to have positive effects on muscle building, endurance, increased HDL (good) and decreased LDL (bad) cholesterol, and body recomposition. Cardarine currently has no human studies, but rodent studies have been very encouraging.
When combined with exercise, GW-501516 combined with four weeks of running increased running time by 68%; running distance by 70%; and doubled overall muscular endurance. Along with exercise GW-501516 increased mitochondrial growth by 50%. Additionally, GW-501516 on its own has been found to activate many of the genes that activate when an organism goes for a run or exercises.
Cardarine is not hormonal so it is not suppressive of endogenous testosterone.
MK-2866, also known as Ostarine or Enobosarm, is one of the best-studied SARMs. It is a non-steroidal selective androgen receptor modifier that strengthens muscle, bone, and tendons. It does not have the negative side effects associated with testosterone such as raising liver, kidney, and prostate enzymes. Elderly men and women who took modest doses of Ostarine for 12 weeks grew 3 pounds of muscle and lost a pound of fat, with no changes to diet or exercise.